Wells Fargo & Company Cellectis S.A. Transaction History

Wells Fargo & Company

  • $468 Billion
  • Q2 2025

A detailed history of Wells Fargo & Company transactions in Cellectis S.A. stock. As of the latest transaction made, Wells Fargo & Company holds 17,150 shares of CLLS stock, worth $53,336. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,150
Previous 22,750 24.62%
Holding current value
$53,336
Previous $28,000 7.14%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$1.15 - $1.65 $6,439 - $9,240
-5,600 Reduced 24.62%
17,150 $26,000
Q1 2025

May 13, 2025
SELL
$1.22 - $2.13 $2,244 - $3,919
-1,840 Reduced 7.48%
22,750 $28,000
Q4 2024

Feb 12, 2025
BUY
$1.51 - $2.14 $18,875 - $26,750
12,500 Added 103.39%
24,590 $44,000
Q3 2024

Nov 13, 2024
SELL
$1.9 - $2.4 $1,330 - $1,680
-700 Reduced 5.47%
12,090 $25,000
Q2 2024

Aug 13, 2024
SELL
$1.86 - $3.35 $279 - $502
-150 Reduced 1.16%
12,790 $23,000
Q1 2024

May 10, 2024
SELL
$2.41 - $3.09 $3,263 - $4,183
-1,354 Reduced 9.47%
12,940 $34,000
Q4 2023

Feb 09, 2024
SELL
$0.97 - $3.55 $1,212 - $4,437
-1,250 Reduced 8.04%
14,294 $44,000
Q3 2023

Nov 13, 2023
SELL
$1.58 - $2.86 $592 - $1,072
-375 Reduced 2.36%
15,544 $24,000
Q2 2023

Aug 15, 2023
SELL
$1.72 - $2.12 $963 - $1,187
-560 Reduced 3.4%
15,919 $31,000
Q1 2023

May 12, 2023
SELL
$1.83 - $3.84 $915 - $1,920
-500 Reduced 2.94%
16,479 $31,000
Q4 2022

Feb 13, 2023
SELL
$1.85 - $2.6 $462 - $650
-250 Reduced 1.45%
16,979 $35,000
Q3 2022

Nov 14, 2022
BUY
$2.29 - $4.08 $12,366 - $22,032
5,400 Added 45.65%
17,229 $40,000
Q2 2022

Aug 12, 2022
SELL
$2.39 - $4.93 $2,629 - $5,423
-1,100 Reduced 8.51%
11,829 $33,000
Q1 2022

May 16, 2022
SELL
$3.45 - $8.77 $22,573 - $57,382
-6,543 Reduced 33.6%
12,929 $59,000
Q4 2021

Feb 14, 2022
SELL
$8.01 - $12.84 $113,325 - $181,660
-14,148 Reduced 42.08%
19,472 $158,000
Q3 2021

Nov 15, 2021
BUY
$11.94 - $16.09 $55,998 - $75,462
4,690 Added 16.21%
33,620 $423,000
Q2 2021

Aug 16, 2021
SELL
$14.36 - $20.93 $22,143 - $32,274
-1,542 Reduced 5.06%
28,930 $448,000
Q1 2021

May 13, 2021
BUY
$18.19 - $33.25 $66,211 - $121,030
3,640 Added 13.57%
30,472 $616,000
Q4 2020

Feb 09, 2021
SELL
$15.87 - $31.64 $21,662 - $43,188
-1,365 Reduced 4.84%
26,832 $726,000
Q3 2020

Nov 05, 2020
SELL
$15.7 - $20.84 $41,934 - $55,663
-2,671 Reduced 8.65%
28,197 $522,000
Q2 2020

Aug 13, 2020
SELL
$8.21 - $21.02 $58,980 - $151,007
-7,184 Reduced 18.88%
30,868 $550,000
Q1 2020

May 14, 2020
BUY
$7.81 - $18.82 $297,186 - $716,138
38,052 New
38,052 $350,000

Others Institutions Holding CLLS

# of Institutions
27
Shares Held
13.2M
Call Options Held
0
Put Options Held
0
View Full List

About Cellectis S.A.

CLLS Quotes by TradingView
  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $142M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email